Cargando…

Immunogenomic correlates of immune-related adverse events for anti–programmed cell death 1 therapy

Despite impressive antitumor efficacy of programmed cell death 1 (PD-1) inhibitors, this inhibition can induce mild to severe autoimmune toxicities, termed immune-related adverse events (irAEs). Yet, predictive pretreatment biomarkers for irAEs development across cancer types remain elusive. We firs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Lei, Shi, Yuankai, Han, Xiaohong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733471/ https://www.ncbi.nlm.nih.gov/pubmed/36505471 http://dx.doi.org/10.3389/fimmu.2022.1032221

Ejemplares similares

Immunogenomic Characteristics of Cell-Death-Associated Genes with Prognostic Implications in Bladder Cancer
por: Xu, Wenhao, et al.
Publicado: (2022)

Investigation of Genetic Determinants of Glioma Immune Phenotype by Integrative Immunogenomic Scale Analysis
por: Zhao, Binghao, et al.
Publicado: (2021)

Immune-related adverse events: A bibliometric analysis
por: Jiang, Shi-Tao, et al.
Publicado: (2022)

Comparative Immunogenomics of Canine Natural Killer Cells as Immunotherapy Target
por: Gingrich, Alicia A., et al.
Publicado: (2021)

Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer
por: Feng, Tao, et al.
Publicado: (2021)

Editorial: Immunogenomics of Solid Organ and Hematopoietic Stem Cell Transplantation
por: Wu, Yongxia, et al.
Publicado: (2022)

Immunogenomic profile at baseline predicts host susceptibility to clinical malaria
por: Mbambo, Gillian, et al.
Publicado: (2023)

Immune-related adverse events of immune checkpoint inhibitors: a review
por: Yin, Qinan, et al.
Publicado: (2023)

Immunogenomic Landscape in Breast Cancer Reveals Immunotherapeutically Relevant Gene Signatures
por: Wang, Tao, et al.
Publicado: (2022)

Correlation Between Immune-Related Adverse Events and Prognosis in Hepatocellular Carcinoma Patients Treated With Immune Checkpoint Inhibitors
por: Xu, Shuo, et al.
Publicado: (2021)

Corrigendum: Immunogenomic landscape in breast cancer reveals immunotherapeutically relevant gene signatures
por: Wang, Tao, et al.
Publicado: (2023)

Anti-PD-1 immune-related adverse events are associated with high therapeutic antibody fixation on T cells
por: Gazzano, Marianne, et al.
Publicado: (2022)

Ophthalmic immune-related adverse events associated with immune checkpoint inhibitors
por: Gan, Linyang, et al.
Publicado: (2023)

Editorial: Genes, diseases, immunity and immunogenomics
por: Siddique, Hifzur R.
Publicado: (2023)

Immune-related adverse events correlate with the efficacy of PD-1 inhibitors combination therapy in advanced cholangiocarcinoma patients: A retrospective cohort study
por: Zhang, Yanfang, et al.
Publicado: (2023)

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events
por: Poto, Remo, et al.
Publicado: (2022)

Correlation of tumor‐infiltrating immune cells of melanoma with overall survival by immunogenomic analysis
por: Huang, Lili, et al.
Publicado: (2020)

Ocular Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Lung Cancer
por: Zhou, Lin, et al.
Publicado: (2021)

External validation of biomarkers for immune-related adverse events after immune checkpoint inhibition
por: Glehr, Gunther, et al.
Publicado: (2022)

Turicibacter and Acidaminococcus predict immune-related adverse events and efficacy of immune checkpoint inhibitor
por: Hamada, Kazuyuki, et al.
Publicado: (2023)

Bibliometric analysis of rheumatic immune related adverse events associated with immune checkpoint inhibitors
por: Zeng, Li, et al.
Publicado: (2023)

Association between germ-line HLA and immune-related adverse events
por: Jiang, Ning, et al.
Publicado: (2022)

Single-Cell Immunogenomic Approach Identified SARS-CoV-2 Protective Immune Signatures in Asymptomatic Direct Contacts of COVID-19 Cases
por: Sen, Kaushik, et al.
Publicado: (2021)

Immunogenomics: a foundation for intelligent immune design
por: Holt, Robert A.
Publicado: (2015)

Characterization and Prognostic Significance of Cutaneous Adverse Events to Anti-Programmed Cell Death-1 Therapy
por: Lee, Ye Jin, et al.
Publicado: (2019)

Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy
por: Jacoberger-Foissac, Celia, et al.
Publicado: (2020)

Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers
por: Maughan, Benjamin L., et al.
Publicado: (2017)

Autoantibody profiles in patients with immune checkpoint inhibitor-induced neurological immune related adverse events
por: Müller-Jensen, Leonie, et al.
Publicado: (2023)

Editorial: Progress of programmed cell death in antitumor immunity
por: Yan, Fangfang, et al.
Publicado: (2023)

The Role of Cytokines in Predicting the Response and Adverse Events Related to Immune Checkpoint Inhibitors
por: Wang, Min, et al.
Publicado: (2021)

Association of immune-related adverse events induced by nivolumab with a battery of autoantibodies
por: Les, Iñigo, et al.
Publicado: (2021)

Changes of peripheral T cell subsets in melanoma patients with immune-related adverse events
por: Müller, Benjamin, et al.
Publicado: (2023)

Intestinal Microbiome Associated With Immune-Related Adverse Events for Patients Treated With Anti-PD-1 Inhibitors, a Real-World Study
por: Liu, Wenhui, et al.
Publicado: (2021)

On the Dark Side of Therapies with Immunoglobulin Concentrates: The Adverse Events
por: Späth, Peter J., et al.
Publicado: (2015)

Immunogenomic approaches to understand the function of immune disease variants
por: Glinos, Dafni A., et al.
Publicado: (2017)

Co-Inhibitory Molecules – Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events
por: Greisen, Stinne R., et al.
Publicado: (2022)

Gut microbiota composition in patients with advanced malignancies experiencing immune-related adverse events
por: Liu, Xinyu, et al.
Publicado: (2023)

Programmed Cell Death Tunes Tumor Immunity
por: Liu, Jing, et al.
Publicado: (2022)

Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study
por: Xie, Xiaohong, et al.
Publicado: (2022)

Penpulimab, an Fc-Engineered IgG1 Anti-PD-1 Antibody, With Improved Efficacy and Low Incidence of Immune-Related Adverse Events
por: Huang, Zhaoliang, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ni6ortln5de26dble5l21oijcf